David Wise, MD, on the potential role for pasritamig plus docetaxel in mCRPC

In an interview at the 2026 ASCO Genitourinary (GU) Cancers Symposium in San Francisco, California, David R. Wise, MD, PhD, discussed encouraging early findings with the investigational bispecific T-cell engager pasritamig combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC).¹ Wise highlighted the regimen’s potential to improve outcomes in patients whose disease has progressed after androgen receptor pathway inhibitor (ARPI) therapy.

Wise is a genitourinary medical oncologist at NYU Langone Health and an associate professor of medicine and urology at the NYU Grossman School of Medicine in New York, New York.

Pasritamig is a first-in-class bispecific antibody that targets CD3 on T cells and kallikrein 2 (KLK2), which is highly expressed in prostate tissue and prostate cancer cells. In the phase 1b study, pasritamig was administered every 6 weeks alongside standard docetaxel dosing, with no observed dose-limiting toxicities. Investigators reported that the combination was readily deliverable at full monotherapy doses, with a safety profile generally consistent with docetaxel alone. Common treatment-related adverse events included fatigue 58.8%), alopecia (41.2%), and diarrhea and nausea (31.4% each). Notably, no cases of cytokine release syndrome were observed.

Wise emphasized that the phase 1b data were particularly notable given the heavily pretreated population enrolled, which included patients with bone-predominant disease and visceral metastases (33%). Across all treated patients, 64.7% achieved a prostate-specific antigen (PSA) decline of at least 50% (PSA50), and 35.3% achieved a PSA decline of at least 90% (PSA90). Responses appeared even stronger in taxane-naïve patients, where confirmed PSA50 reached 75.0% and PSA90 was 46.4%. Wise noted that these results compare favorably with historical expectations for docetaxel alone, suggesting that adding pasritamig may provide additive benefit and possibly synergistic activity.

Looking ahead, Wise highlighted the ongoing phase 3 KLK2-PASenger trial (NCT07225946), which is evaluating the combination in patients with post-ARPI mCRPC, including those with bone and visceral metastases. He said the study is strategically positioned for patients who remain candidates for docetaxel, an agent that continues to play an important role despite the expansion of newer therapies. If the phase 3 trial confirms the promising efficacy and tolerability seen in earlier testing, Wise said pasritamig plus docetaxel could emerge as a new standard option for docetaxel-eligible patients with mCRPC.

REFERENCE
1. Patel M. Safety and efficacy of pasritamig (PAS) + docetaxel (DOCE) in participants with metastatic castration-resistant prostate cancer (mcrPc): Initial results of a phase 1b study. Presented at: 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium. February 26-28, 2026. San Francisco, California. Abstract 171. https://www.asco.org/abstracts-presentations/256425